Latest revenue
$83.1M
as of 2026-03-31
Latest net income
$-31.6M
as of 2026-03-31
Net margin
-38.1%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $1.65B
- Enterprise value
- $1.65B
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $66.85
- 52-wk low
- $19.35
- Beta
- —
- Shares out
- 56.9M
5-year trend
What this company does
Item 1. Business Overview We are a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. We develop, manufacture and sell the AquaBeam Robotic System and HYDROS Robotic System, which are advanced, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. Each of our robotic systems employs a single-use disposable handpiece to deliver our proprietary Aquablation therapy, which combines real-time, multi-dimensional imaging, personalized…
AI summary unavailable — showing raw filing excerpt
Generated from PRCT's filing dated 2026-02-26
Key risks
Table of Contents Item 1A. Risk Factors Our operations and financial results are subject to various risks and uncertainties including those described below. You should consider carefully the risks and uncertainties described below, in addition to other information contained in this Annual Report on Form 10-K, including our consolidated financial statements and related notes. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that adversely affect our business. If any of the following risks or others not specified below…
AI summary unavailable — showing raw filing excerpt
Generated from PRCT's filing dated 2026-02-26
Profitability
Gross margin
63.7%
4.3%Operating margin
-33.7%
21.7%Net margin
-31.0%
23.8%Return on equity
-23.8%
4.5%Return on assets
-18.8%
9.9%Leverage
Debt / equity
0.26×
19.7%Long-term debt / equity
0.13×
0.3%Debt / assets
20.8%
15.6%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $83.1M | +20.2% | $-31.6M | -27.9% | -38.1% |
Q4 2025 2025-12-31 | $76.4M | +11.9% | $-29.8M | -58.3% | -39.1% |
Q3 2025 2025-09-30 | $83.3M | +42.8% | $-21.4M | -2.1% | -25.7% |
Q2 2025 2025-06-30 | $79.2M | +48.4% | $-19.6M | +23.6% | -24.7% |
Q1 2025 2025-03-31 | $69.2M | +55.3% | $-24.7M | +4.7% | -35.8% |
Q4 2024 2024-12-31 | $68.2M | — | $-18.9M | — | -27.6% |
Q3 2024 2024-09-30 | $58.4M | +66.3% | $-21.0M | +14.8% | -35.9% |
Q2 2024 2024-06-30 | $53.4M | +61.2% | $-25.6M | -1.3% | -48.0% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Surgical & Medical Instruments & Apparatus · SIC 3841
Your notes
Keep private notes on PRCT — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$11.3M
Insider selling
$11.2M
Net activity
+$30.6K
Distinct insiders
5
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns PRCT
Institutional value
$631.2M
Total shares held
25.8M
Distinct holders
153
-104 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 4.4M | $109.1M | +15.0K (+0.3%) | Added |
| 2 | VANGUARD PORTFOLIO MANAGEMENT LLC | 2.4M | $60.6M | — | New |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 2.4M | $60.0M | — | New |
| 4 | Chicago Capital, LLC | 2.2M | $54.0M | +969.6K (+81.4%) | Added |
| 5 | MACKENZIE FINANCIAL CORP | 1.7M | $43.0M | +147.3K (+9.4%) | Added |
| 6 | Artisan Partners Limited Partnership | 1.2M | $29.7M | -333.4K (-21.9%) | Trimmed |
| 7 | Champlain Investment Partners, LLC | 1.1M | $28.4M | -304.7K (-21.1%) | Trimmed |
| 8 | BAILLIE GIFFORD & CO | 973.5K | $24.3M | -42.5K (-4.2%) | Trimmed |
| 9 | Fiera Capital Corp | 967.6K | $24.2M | +691.1K (+250.0%) | Added |
| 10 | UBS Group AG | 504.5K | $12.6M | -548.5K (-52.1%) | Trimmed |
| 11 | NEW YORK STATE COMMON RETIREMENT FUND | 440.1K | $11.0M | +108.9K (+32.9%) | Added |
| 12 | WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 424.3K | $10.6M | +8.1K (+1.9%) | Added |
| 13 | VANGUARD FIDUCIARY TRUST CO | 384.3K | $9.6M | — | New |
| 14 | JOHNSON & JOHNSON | 357.9K | $9.0M | -357.9K (-50.0%) | Trimmed |
| 15 | HSBC HOLDINGS PLC | 338.9K | $8.5M | — | New |
| 16 | BLAIR WILLIAM & CO/IL | 323.9K | $8.1M | +113.7K (+54.1%) | Added |
| 17 | CITIGROUP INC | 322.7K | $8.1M | +178.1K (+123.2%) | Added |
| 18 | JPMORGAN CHASE & CO | 271.2K | $6.9M | +224.1K (+475.3%) | Added |
| 19 | Granite Investment Partners, LLC | 252.0K | $6.3M | -13.6K (-5.1%) | Trimmed |
| 20 | WASATCH ADVISORS LP | 222.6K | $5.6M | +232 (+0.1%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once PRCT's latest filing finishes processing.